Inhibikase Therapeutics (IKT) Competitors $1.77 -0.08 (-4.32%) Closing price 04:00 PM EasternExtended Trading$1.80 +0.03 (+1.69%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IKT vs. PGEN, ARVN, TBPH, SAGE, ORGO, TSHA, ABVX, BCYC, BCAX, and ORKAShould you be buying Inhibikase Therapeutics stock or one of its competitors? The main competitors of Inhibikase Therapeutics include Precigen (PGEN), Arvinas (ARVN), Theravance Biopharma (TBPH), Sage Therapeutics (SAGE), Organogenesis (ORGO), Taysha Gene Therapies (TSHA), Abivax (ABVX), Bicycle Therapeutics (BCYC), Bicara Therapeutics (BCAX), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry. Inhibikase Therapeutics vs. Its Competitors Precigen Arvinas Theravance Biopharma Sage Therapeutics Organogenesis Taysha Gene Therapies Abivax Bicycle Therapeutics Bicara Therapeutics Oruka Therapeutics Precigen (NASDAQ:PGEN) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Do institutionals and insiders hold more shares of PGEN or IKT? 33.5% of Precigen shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 47.1% of Precigen shares are held by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has stronger earnings & valuation, PGEN or IKT? Inhibikase Therapeutics has lower revenue, but higher earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecigen$3.92M118.22-$126.24M-$0.56-2.80Inhibikase TherapeuticsN/AN/A-$19.03M-$2.67-0.66 Which has more risk and volatility, PGEN or IKT? Precigen has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Is PGEN or IKT more profitable? Inhibikase Therapeutics has a net margin of 0.00% compared to Precigen's net margin of -3,728.87%. Precigen's return on equity of -279.20% beat Inhibikase Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Precigen-3,728.87% -279.20% -79.74% Inhibikase Therapeutics N/A -350.63%-201.82% Does the media favor PGEN or IKT? In the previous week, Precigen had 2 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 3 mentions for Precigen and 1 mentions for Inhibikase Therapeutics. Precigen's average media sentiment score of 1.02 beat Inhibikase Therapeutics' score of 0.67 indicating that Precigen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precigen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibikase Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer PGEN or IKT? Precigen currently has a consensus target price of $6.00, suggesting a potential upside of 282.17%. Inhibikase Therapeutics has a consensus target price of $6.50, suggesting a potential upside of 267.23%. Given Precigen's stronger consensus rating and higher probable upside, equities analysts plainly believe Precigen is more favorable than Inhibikase Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precigen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Inhibikase Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryPrecigen beats Inhibikase Therapeutics on 12 of the 15 factors compared between the two stocks. Get Inhibikase Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IKT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKT vs. The Competition Export to ExcelMetricInhibikase TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$131.59M$273.51M$5.70B$21.12BDividend YieldN/AN/A4.69%3.60%P/E Ratio-0.66N/A28.0728.44Price / SalesN/A364.38448.5760.38Price / CashN/A22.4436.2222.92Price / Book0.9912.418.664.69Net Income-$19.03M-$106.40M$3.25B$995.51M7 Day Performance-3.80%4.86%4.20%1.64%1 Month Performance5.99%25.43%10.82%5.92%1 Year Performance10.63%11.08%34.70%11.50% Inhibikase Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKTInhibikase Therapeutics1.484 of 5 stars$1.77-4.3%$6.50+267.2%+12.8%$131.59MN/A-0.666News CoveragePGENPrecigen3.8466 of 5 stars$1.95+6.6%$6.00+207.7%-2.1%$575.60M$4.20M-3.48190Positive NewsARVNArvinas4.0032 of 5 stars$7.87+1.0%$20.29+157.8%-72.7%$574.43M$263.40M-11.92420News CoverageUpcoming EarningsTBPHTheravance Biopharma1.7803 of 5 stars$11.47+1.5%$16.60+44.7%+11.3%$573.50M$64.38M-9.72110SAGESage Therapeutics3.4224 of 5 stars$9.15-1.3%$8.75-4.4%-15.6%$572.97M$41.24M-1.58690Upcoming EarningsORGOOrganogenesis4.5372 of 5 stars$4.49+4.4%$6.00+33.6%+53.2%$569.56M$482.04M-26.41950TSHATaysha Gene Therapies4.2565 of 5 stars$2.64flat$8.17+209.3%+15.6%$566.70M$8.33M-7.76180ABVXAbivax2.4067 of 5 stars$8.83+6.8%$31.00+251.1%+488.7%$560.44MN/A0.0061Trending NewsAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeBCYCBicycle Therapeutics3.8213 of 5 stars$8.08+1.0%$25.00+209.4%-63.5%$559.54M$35.28M-2.57240BCAXBicara Therapeutics2.0924 of 5 stars$10.18+4.8%$31.86+213.0%N/A$555.22MN/A0.0032ORKAOruka Therapeutics2.6959 of 5 stars$14.70+3.3%$40.38+174.7%N/A$550.37MN/A-3.26N/AUpcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies PGEN Alternatives ARVN Alternatives TBPH Alternatives SAGE Alternatives ORGO Alternatives TSHA Alternatives ABVX Alternatives BCYC Alternatives BCAX Alternatives ORKA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:IKT) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IKT Stock Alerts